Quantcast
Last updated on April 23, 2014 at 21:24 EDT

WomanCare Global to Distribute Mifepristone in Europe and Africa

February 9, 2012

Increasing access to mifepristone to improve women’s reproductive health choices

LONDON, Feb. 9, 2012 /PRNewswire-USNewswire/ — WomanCare Global announced today that mifepristone has been added to their reproductive healthcare portfolio. Through an agreement with Linepharma, WomanCare Global will provide sales, marketing, provider training and distribution of mifepristone in seven European and seven African countries.

(Logo: http://photos.prnewswire.com/prnh/20101018/DC83896LOGO )

Linepharma’s mifepristone is labeled for use as a single 200mg tablet of mifepristone to perform medical abortion in conjunction with a prostaglandin, in compliance with the World Health Organization’s recommendation. Linepharma’s mifepristone is manufactured in Europe and is currently approved in five E.U. countries.

The planned distribution of mifepristone by WomanCare Global in 14 countries will ensure that close to 55 million women will have another safe, quality product to manage their reproductive health.

To date, a European-approved mifepristone has only been available in a limited geographic area,” said WomanCare Global CEO Saundra Pelletier. “Providing access to quality reproductive health supplies ensures that women can choose if and when to have children. This is a critical factor in helping women live to their fullest potential.”

Teaming with WomanCare Global is an achievement for Linepharma which has been built with the aim to bring products approved by the most demanding regulatory agencies and to provide not-for-profit organizations with pharmaceutical support in order to allow women in developing countries to get access to high-quality medicines” said Linepharma General Manager Thomas Kozminski.

“In our many years of working in women’s reproductive health, we are very aware of the unmet need for higher quality products. We are so pleased that WomanCare Global is able to provide a solution and make an EU-manufactured mifepristone available to the women we serve,” said Ipas CEO Liz Maguire. “Ipas will work very closely with WomanCare Global on expanding access to mifepristone in Africa. Bringing this life saving technology to women in low-resource settings is critical to reducing deaths and injuries from unsafe abortion and helping women make their own reproductive decisions.”

About WomanCare Global
WomanCare Global is a nonprofit organization working with partners around the world to improve the lives of women by providing access to affordable, quality reproductive health products. The organization believes that every woman, no matter where she lives, should have control over her reproductive health and family planning needs, ultimately improving her ability to care for herself and her family. WomanCare Global closes the access gap by bringing the same quality products available in the developed world to developing countries. WomanCare Global serves both public and private sectors via an established global supply chain reaching countries around the world, with particular focus on under-served markets in Africa, Asia and Latin America. WomanCare Global was established by Ipas in 2009 and the two organizations continue to work closely together. WomanCare Global operates independently as a UK Registered Charity (No. 1138896). For more information, please visit womancareglobal.org

About Linepharma
Linepharma is a European pharmaceutical company which identifies, develops and registers medicines or medical devices which offer health benefits to women and need specific approaches for commercialization. Currently, the company is focused to make medical abortion safe and affordable and to develop medicines for the treatment and prevention of ob/gyn conditions such as post-partum haemorrhage. Linepharma contributes to training services related to the use of its medicines in developed and developing countries.

SOURCE WomanCare Global


Source: PR Newswire